What sector does Halozyme Therapeutics, Inc (HALO) operate in?
Halozyme Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Halozyme Therapeutics, Inc (HALO) current stock price?
As of the latest data, Halozyme Therapeutics, Inc stock price is $67.88, with a previous close of $68.05. Halozyme Therapeutics, Inc lost -$0.17 in the last trading session, representing a -0.25% loss.
What is Halozyme Therapeutics, Inc (HALO) current market capitalization?
Halozyme Therapeutics, Inc market cap is approximately 7.98 billion.
What is Halozyme Therapeutics, Inc (HALO) Earnings Per Share (EPS)?
The trailing EPS is $4.74, and the forward EPS is $9.85.
What is Halozyme Therapeutics, Inc (HALO) Price-to-Earnings (P/E) ratio?
Halozyme Therapeutics, Inc current P/E ratio is 14.32, with a forward P/E of 6.89.
What is Halozyme Therapeutics, Inc (HALO) EBITDA?
Halozyme Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 281.08 million.
Does Halozyme Therapeutics, Inc (HALO) pay dividends?
No. Halozyme Therapeutics, Inc does not pay a dividend.
How did Halozyme Therapeutics, Inc (HALO) perform in its most recent earnings report?
In the last report (December 31, 2025), Halozyme Therapeutics, Inc posted an EPS surprise of -112.63% and a revenue surprise of -67.58%.
When is Halozyme Therapeutics, Inc (HALO) next earnings report?
Halozyme Therapeutics, Inc is expected to release its next earnings report on March 31, 2026.
What is Halozyme Therapeutics, Inc (HALO) beta (volatility) score?
Halozyme Therapeutics, Inc has a beta of 0.977, meaning its volatility is roughly in line with the market.